Literature DB >> 30013655

Fusobacterium nucleatum promotes the progression of colorectal cancer by interacting with E-cadherin.

Chun-Ting Ma1, He-Sheng Luo1, Feng Gao2, Qin-Cai Tang1, Wei Chen1.   

Abstract

Increasing evidence suggests that Fusobacterium nucleatum is involved in colorectal carcinogenesis. Previous studies have explored whether F. nucleatum may trigger colonic epithelial-mesenchymal transition. The results of the present study demonstrated that F. nucleatum enhances the proliferation and invasion of NCM460 cells compared with that of normal control and DH5α cells. Furthermore, F. nucleatum significantly increased the phosphorylation of p65 (a subunit of nuclear factor-κB), as well as the expression of interleukin (IL)-6, IL-1β and matrix metalloproteinase (MMP)-13. Additionally, F. nucleatum infection did not affect the expression levels of epithelial (E-)cadherin and β-catenin. E-cadherin knockdown in NCM460 cells did not induce the activation of inflammatory responses in response to F. nucleatum infection, whereas it increased inflammation in response to β-catenin silencing. F. nucleatum infection could not increase the proportion of cells at S phase when E-cadherin was silenced. Nevertheless, F. nucleatum infection enhanced the proportion of NCM460 cells at S phase when transfected with small interfering RNAs to knock down β-catenin expression. In conclusion, the results of the present study demonstrated that F. nucleatum infection interacted with E-cadherin instead of β-catenin, which in turn enhances the malignant phenotype of colorectal cancer cells.

Entities:  

Keywords:  Fusobacterium nucleatum; colorectal carcinogenesis; epithelial cadherin; epithelial-mesenchymal transition; β-catenin

Year:  2018        PMID: 30013655      PMCID: PMC6036566          DOI: 10.3892/ol.2018.8947

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  29 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.

Authors:  Aleksandar D Kostic; Eunyoung Chun; Lauren Robertson; Jonathan N Glickman; Carey Ann Gallini; Monia Michaud; Thomas E Clancy; Daniel C Chung; Paul Lochhead; Georgina L Hold; Emad M El-Omar; Dean Brenner; Charles S Fuchs; Matthew Meyerson; Wendy S Garrett
Journal:  Cell Host Microbe       Date:  2013-08-14       Impact factor: 21.023

4.  Fusobacterium nucleatum subspecies identification by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Shuping Nie; Baoyu Tian; Xiaowei Wang; David H Pincus; Martin Welker; Kathleen Gilhuley; Xuedong Lu; Yiping W Han; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

Review 5.  Interplay Between Transcription Factors and MicroRNAs Regulating Epithelial-Mesenchymal Transitions in Colorectal Cancer.

Authors:  Markus Kaller; Heiko Hermeking
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

6.  NF-κB decoy polyplexes decrease P-glycoprotein-mediated multidrug resistance in colorectal cancer cells.

Authors:  N H Abd Ellah; L Taylor; N Ayres; M M Elmahdy; G N Fetih; H N Jones; E A Ibrahim; G M Pauletti
Journal:  Cancer Gene Ther       Date:  2016-04-29       Impact factor: 5.987

Review 7.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

8.  Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue.

Authors:  Raaj S Mehta; Reiko Nishihara; Yin Cao; Mingyang Song; Kosuke Mima; Zhi Rong Qian; Jonathan A Nowak; Keisuke Kosumi; Tsuyoshi Hamada; Yohei Masugi; Susan Bullman; David A Drew; Aleksandar D Kostic; Teresa T Fung; Wendy S Garrett; Curtis Huttenhower; Kana Wu; Jeffrey A Meyerhardt; Xuehong Zhang; Walter C Willett; Edward L Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

9.  Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade.

Authors:  Yongyu Chen; Yan Peng; Jiahui Yu; Ting Chen; Yaxin Wu; Lei Shi; Qing Li; Jiao Wu; Xiangsheng Fu
Journal:  Oncotarget       Date:  2017-05-09

10.  Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

Authors:  Chamutal Gur; Yara Ibrahim; Batya Isaacson; Rachel Yamin; Jawad Abed; Moriya Gamliel; Jonatan Enk; Yotam Bar-On; Noah Stanietsky-Kaynan; Shunit Coppenhagen-Glazer; Noam Shussman; Gideon Almogy; Angelica Cuapio; Erhard Hofer; Dror Mevorach; Adi Tabib; Rona Ortenberg; Gal Markel; Karmela Miklić; Stipan Jonjic; Caitlin A Brennan; Wendy S Garrett; Gilad Bachrach; Ofer Mandelboim
Journal:  Immunity       Date:  2015-02-10       Impact factor: 31.745

View more
  15 in total

Review 1.  Role of gut microbiota in epigenetic regulation of colorectal Cancer.

Authors:  Yinghui Zhao; Chuanxin Wang; Ajay Goel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-13       Impact factor: 10.680

Review 2.  Pathogenic Mechanisms of Fusobacterium nucleatum on Oral Epithelial Cells.

Authors:  Sabine Groeger; Yuxi Zhou; Sabine Ruf; Joerg Meyle
Journal:  Front Oral Health       Date:  2022-04-05

Review 3.  Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents.

Authors:  Carmen Garrido-Navas; Diego de Miguel-Perez; Jose Exposito-Hernandez; Clara Bayarri; Victor Amezcua; Alba Ortigosa; Javier Valdivia; Rosa Guerrero; Jose Luis Garcia Puche; Jose Antonio Lorente; Maria José Serrano
Journal:  Cells       Date:  2019-11-03       Impact factor: 6.600

Review 4.  Potential Use of Biotherapeutic Bacteria to Target Colorectal Cancer-Associated Taxa.

Authors:  Garreth W Lawrence; Máire Begley; Paul D Cotter; Caitriona M Guinane
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

Review 5.  Gut Microbiota and Colorectal Cancer Development: A Closer Look to the Adenoma-Carcinoma Sequence.

Authors:  Marco Vacante; Roberto Ciuni; Francesco Basile; Antonio Biondi
Journal:  Biomedicines       Date:  2020-11-10

Review 6.  Dietary Factors Modulating Colorectal Carcinogenesis.

Authors:  Filippo Vernia; Salvatore Longo; Gianpiero Stefanelli; Angelo Viscido; Giovanni Latella
Journal:  Nutrients       Date:  2021-01-03       Impact factor: 5.717

Review 7.  Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes.

Authors:  Federica Gaiani; Federica Marchesi; Francesca Negri; Luana Greco; Alberto Malesci; Gian Luigi de'Angelis; Luigi Laghi
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

Review 8.  The E-Cadherin Cleavage Associated to Pathogenic Bacteria Infections Can Favor Bacterial Invasion and Transmigration, Dysregulation of the Immune Response and Cancer Induction in Humans.

Authors:  Christian A Devaux; Soraya Mezouar; Jean-Louis Mege
Journal:  Front Microbiol       Date:  2019-11-08       Impact factor: 5.640

9.  FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2.

Authors:  Pin Guo; Zibin Tian; Xinjuan Kong; Lin Yang; Xinzhi Shan; Bingzi Dong; Xueli Ding; Xue Jing; Chen Jiang; Na Jiang; Yanan Yu
Journal:  J Exp Clin Cancer Res       Date:  2020-09-29

10.  Growth rate alterations of human colorectal cancer cells by 157 gut bacteria.

Authors:  Rahwa Taddese; Daniel R Garza; Lilian N Ruiter; Marien I de Jonge; Clara Belzer; Steven Aalvink; Iris D Nagtegaal; Bas E Dutilh; Annemarie Boleij
Journal:  Gut Microbes       Date:  2020-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.